Bristol Myers Squibb and Hengrui Pharma launched a global research pact spanning 13 early development programs across oncology, hematology and immunology, with deal terms reported as up to $15.2 billion. BMS will hold rights outside mainland China, while Hengrui keeps exclusive control in China, Hong Kong and Macau.